Drug Database
AN

anti-H5N1 avian influenza antibodies (Fabenflu / FBF001)

✓ Approved

Fab'entech · Polyclonal Antibodies · Polyclonal Antibodies

What is anti-H5N1 avian influenza antibodies?

anti-H5N1 avian influenza antibodies is a polyclonal antibodies developed by Fab'entech. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesFabenflu, FBF001
CompanyFab'entech
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Fab'entech

Therapeutic Indications

anti-H5N1 avian influenza antibodies is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsInfluenza✓ Approved

Related Research Articles

PubMedMicrobiology resource announcements2026-10-16

Whole genome sequences of highly pathogenic H5N1 avian influenza viruses detected in felines in Bangladesh.

Hayat Sajedul S, Badhy Shukes Chandra SC, Hossain Mohammad Enayet ME, Kundu Ashis Kumar AK et al.

Whole-genome sequences of three highly pathogenic H5N1 avian influenza viruses detected in cats in Bangladesh during 2025-2026 are reported. Phylogenetically, two strains grouped within clade 2.3.2.1a, and the other within the clade 2.3.4.4b. The isolates harbored mutations in key polymerase and HA markers associated with mammalian adaptation and virulence.

PMID 42885913
Read full article →
PubMedChemical biology & drug design2026-10-16

DNAzymes and Oligodeoxyribonucleotides Immobilized on Aminopropylsilanol and Polylysine-Anatase Nanoparticles as Active Agents Against Influenza A/H5N1 Virus.

Repkova Marina M, Levina Asya A, Filippova Ekaterina E, Makarevich Elena E et al.

The nanocomposites based on aminopropylsilanol (Si~NH2) and polylysine-anatase (Ans/PL) nanoparticles bearing DNAzymes (Dz) and oligodeoxyribonucleotides (ON) can effectively inhibit the replication of the influenza A/H5N1 virus in cell culture. Nanocomposites based on both types of nanoparticles exhibit high activity. The Dz-containing nanocomposites exhibited higher antiviral activity than those containing ON, reducing influenza A/H5N1 virus production by 3.5 log versus 2.4-3.0 log, respectively. Notably, the effect of Dz incorporated into the nanoparticles was an order of magnitude higher than that of unbound Dz transfected with lipofectamine. Nanocomposites carrying control DNA fragments that are not specific to the influenza A virus genome have practically no antiviral activity, indicating the specificity of the proposed nanocomposites. It was demonstrated that the antiviral efficacy of the nanocomposites is primarily determined by the activity of DNA delivered into cells, which can be varied by altering either the nanocomposite concentration or its capacity for DNA fragments. All of the proposed nanocomposites can be considered as potential antiviral drugs.

PMID 42885400
Read full article →
PubMedBMC public health2026-10-16

Enhancing knowledge on influenza and other pandemic threats for healthcare personnel readiness in Thailand, 2007-2024.

Sawanpanyalert Narumol N, Praphasiri Prabda P, Ditsungnoen Darunee D, Tantilipikara Peangpim P et al.

Healthcare personnel are often the first line of defense against emerging diseases. Enhancing knowledge on influenza for healthcare personnel is part of Thailand's influenza pandemic preparedness plan. Beginning in 2007, the Thailand Department of Medical Services organized trainings for Thai healthcare personnel in Bangkok and all regions of Thailand on prevention, diagnosis, treatment, and control of human seasonal, avian, and pandemic influenza. The curriculum included overviews on the global situation, clinical features and treatment, influenza epidemiology and burden in Thailand, influenza as a cause of pneumonia, laboratory diagnostics, impact of influenza in high-risk populations and increased risk for complications; influenza economic evaluation of seasonal influenza vaccination in Thailand, and immunization and planning for human influenza outbreaks. Topics initially focused on seasonal and pandemic influenza and expanded in scope to incorporate other pandemic threats, such as MERS-CoV and COVID-19. From August 2007 through December 2024, 114 trainings were conducted. A total of 26,422 attendees (range 10-700 per training) were trained, including clinicians, nurses, pharmacists, laboratory technicians, and public health scientists (professionals trained in epidemiology, disease surveillance, and health data analysis) from public and private hospitals from national, regional, provincial, and district levels in Bangkok and 41 provinces nationwide. During training sessions, participants reported that the program increased their readiness and self-reported confidence to respond to potential respiratory outbreaks. These capacity-building efforts contributed to a health workforce that was better positioned to respond to emerging respiratory threats, including the first wave of COVID-19. Educating healthcare personnel about prevention, diagnosis, treatment, and control of influenza is an important component of pandemic preparedness. Refresher courses or online tutorials may be needed periodically to maintain current knowledge.

PMID 42881450
Read full article →
PubMedInternational journal of molecular sciences2026-10-16

Endothelin-1 and Anticardiolipin Antibodies in Primary Biliary Cholangitis Patients with Portal Hypertension: A Pilot Retrospective Study.

Bauer Alicja A, Rawa Tomasz T, Bauer Tomasz T

Primary biliary cholangitis (PBC) is a chronic autoimmune, cholestatic liver disease leading to fibrosis, cirrhosis, and portal hypertension. Endothelin-1 (ET-1), a potent vasoconstrictor with profibrotic properties, has been implicated in the pathogenesis of liver fibrosis and portal hypertension. Anti-cardiolipin antibodies (aCL) may further contribute to disease progression by promoting thrombotic complications. Our aim was to evaluate serum ET-1 concentrations and anti-cardiolipin antibody levels in PBC patients and their association with portal hypertension. Serum samples from 80 patients with PBC, including patients with portal hypertension, and 25 healthy controls were analyzed. ET-1 concentrations and anti-cardiolipin antibodies were measured using commercially available immunoassays. Elevated serum ET-1 levels were detected in 84% of patients with PBC and portal hypertension and the ET-1 concentrations were also significantly higher in this group compared to the control group. Serum ET-1 levels positively correlated with total bilirubin concentrations and the severity of histological fibrosis. Anti-cardiolipin antibodies were detected in 32% of PBC patients with portal hypertension. Elevated serum ET-1 concentrations and the presence of anti-cardiolipin antibodies are associated with advanced liver disease and portal hypertension in patients with PBC. These biomarkers may have potential value in identifying patients at increased risk of disease progression and worsening liver function.

PMID 42883709
Read full article →
PubMedHuman gene therapy2026-10-16

Complement Activation Within Minutes Following Systemic Administration of AAV in the Presence of AAV Immunity.

Caragiulo Anthony A, Rosenberg Jonathan B JB, De Bishnu P BP, Kaminsky Stephen M SM et al.

A challenge of adeno-associated virus (AAV)-mediated gene therapy is the high prevalence of preexisting anticapsid antibodies, which can reduce vector efficacy and, after high-dose systemic administration, promote formation of antibody-vector complexes that activate complement. Complement-mediated toxicities reported after systemic AAV administration have generally been observed several days after dosing. However, observations in nonhuman primates (NHPs) suggested that complement activation may occur within minutes of vector exposure in the presence of anti-AAV antibodies. To characterize this response, we evaluated complement activation following repeat systemic administration of AAVrh.10 vectors in African Green monkeys and assessed early and delayed time points when NHPs were seronegative and seropositive for anti-AAV antibodies. Five NHPs received intravenous AAVrh.10 vectors (1 × 1013 gc/kg) administered 42 days apart. Three animals received AAVrh.10 expressing human C1 esterase inhibitor and two received a transgene-null vector. Serum samples were collected from 10 min to 42 days after the first administration and from 10 min to 21 days after the second. Complement activation was assessed by measuring serum terminal complement complex (TCC) levels and anti-AAVrh.10 immunoglobulin G (IgG) titers were used to monitor humoral immunity. Vector administrations were well tolerated, with no treatment-related abnormalities. Following the initial dose, all animals developed robust anti-AAVrh.10 IgG responses that increased after readministration. No significant complement activation was observed after the first administration. In contrast, in the presence of anti-AAVrh.10 antibodies, all animals demonstrated rapid increases in TCC within 10 min of the second administration, reaching 10-fold above baseline and returning to baseline by 1 day. Complement activation was observed in animals with antivector titers >1/104, whereas little or no response was detected at titers <1/103. These findings identify rapid, transient complement activation as an underrecognized response to systemic AAV administration in the presence of anti-AAV antibodies and support complement monitoring during the first hour after vector dosing in clinical gene therapy studies.

PMID 42885510
Read full article →
PubMedAmerican family physician2026-10-16

Influenza: Prevention, Diagnosis, and Treatment.

Sur Denise K C DKC, Khoo Catherine Peony CP

Influenza is typically a self-limiting viral infection that causes symptoms such as fever, chills, cough, rhinitis, headache, sweats, myalgias, and malaise. However, serious illness and complications (eg, pneumonia, death) can occur, particularly in individuals with risk factors. Annual influenza vaccination is recommended for people 6 months and older, including pregnant individuals, who do not have a contraindication to the vaccine. Rapid diagnosis of influenza using point-of-care testing in select patients increases antiviral prescribing and decreases antibiotic prescribing in those with a positive result. However, a negative rapid test result does not exclude influenza. Although most patients do not require treatment for influenza, antivirals should be initiated as soon as possible for patients who are hospitalized, have severe or progressive illness, or are at high risk of complications. Treatment can be considered in symptomatic patients who are household contacts of individuals at high risk of complications or in symptomatic health care professionals who care for patients at risk. Postexposure chemoprophylaxis with antiviral therapies can be considered in individuals who are at risk for influenza complications. Oseltamivir and baloxavir marboxil are commonly recommended antiviral treatment options for influenza. Antiviral treatment is most effective if taken within 24 to 36 hours of symptom onset and reduces symptoms by approximately 20 hours. However, there is little to no evidence that it reduces complications of influenza.

PMID 42886183
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about anti-H5N1 avian influenza antibodies